{"organizations": [], "uuid": "7a49252b4f01db363197c635955a1821bc2d534a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180403.html", "section_title": "Archive News &amp; Video for Tuesday, 03 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-pfizer-and-allogene-enter-into-agr/brief-pfizer-and-allogene-enter-into-agreement-for-pfizers-car-t-cell-therapy-idUSB8N1RG000", "country": "US", "domain_rank": 408, "title": "BRIEF-Pfizer and Allogene enter into agreement for Pfizer's CAR T cell therapy", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.625, "site_type": "news", "published": "2018-04-03T21:11:00.000+03:00", "replies_count": 0, "uuid": "7a49252b4f01db363197c635955a1821bc2d534a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-pfizer-and-allogene-enter-into-agr/brief-pfizer-and-allogene-enter-into-agreement-for-pfizers-car-t-cell-therapy-idUSB8N1RG000", "ord_in_thread": 0, "title": "BRIEF-Pfizer and Allogene enter into agreement for Pfizer's CAR T cell therapy", "locations": [], "entities": {"persons": [{"name": "allogene", "sentiment": "negative"}], "locations": [{"name": "allogene", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "pfizer", "sentiment": "negative"}, {"name": "pfizer inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "servier", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 3 (Reuters) - Pfizer Inc:\n* SAYS CO AND ALLOGENE THERAPEUTICS ENTER INTO ASSET CONTRIBUTION AGREEMENT FOR PFIZER’S ALLOGENEIC CAR T IMMUNO-­ONCOLOGY PORTFOLIO\n* SAYS AGREEMENT AIMS TO ACCELERATE THE DEVELOPMENT OF PFIZER’S CAR T CELL THERAPY\n* SAYS ALLOGENE WILL RECEIVE RIGHTS FROM CO TO 16 PRE-CLINICAL CAR T ASSETS LICENSED FROM CELLECTIS AND SERVIER\n* SAYS ALLOGENE WILL RECEIVE RIGHTS TO ONE CLINICAL ASSET FROM SERVIER CALLED UCART19\n* SAYS CO WILL HOLD 25 PERCENT STAKE IN ALLOGENE THERAPEUTICS; CO WILL BE REPRESENTED ON ALLOGENE’S BOARD Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-03T21:11:00.000+03:00", "crawled": "2018-04-04T12:40:57.022+03:00", "highlightTitle": ""}